Australian regulators have issued a "hazard alert" warning that a manufacturing snafu may cause a version of Medtronic's Consulta pacemaker to take in bodily fluid and then malfunction. But another model has also displayed problems; the company says it has recalled affected batches of both, and also notified surgeons.
Nanostim says its tiny wireless cardiac pacemaker has shown some success in its first three human patients, early signs that the potentially disruptive technology has legs. And the company's advance, presented this week at the Heart Rhythm Society meeting in Denver, may give it the lead over larger medical device rivals trying to come up with something similar.
Medtronic gained FDA approval for what will become its second MRI-friendly pacer in the United States, and only the second device of its kind to gain a regulatory nod here.
The FDA approved a clinical trial of Biotronik's proMRI pacemaker, a device designed to operate without a hitch during an MRI. Over concerns that traditional pacemakers may be unsafe during the procedure, several companies have recently developed devices that can be marketed with MRI compatability mind.
Nanostim, a small California startup, says it has successfully implanted a leadless cardiac pacemaker into 11 patients at a hospital in the Czech republic.
Underagers with implantable defibrillators and pacemakers report having a lower quality of life than other kids, according to a new study, suggesting to researchers that implants ought to be coupled with support systems.
Consider this: A pacemaker powered by your own beating heart. Scientists at the Department of Aerospace Engineering at the University of Michigan in Ann Arbor are developing some snazzy new technology with that very goal in mind.
Would you recycle a pacemaker from an autopsy, and use it in someone else? A new study by researchers at the University of Pennsylvania and highlighted in Reuters concludes the practice could be feasible.
With PMA supplement in hand, Medtronic ($MDT) is launching a new wireless remote monitoring system designed to speed up hospital treatment decisions for patients with the company's implanted cardiac devices.
After the financial week that Boston Scientific ($BSX) just endured, interim CEO Hank Kucheman came on with a strong dose of optimism, insisting he believes revenue will resume growing starting in 2013.